Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
13 hedge funds and large institutions have $22.2M invested in Bellerophon Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
165% more capital invested
Capital invested by funds: $8.35M → $22.2M (+$13.8M)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
4.1% less ownership
Funds ownership: 50.07% → 45.97% (-4.1%)
13% less funds holding
Funds holding: 15 → 13 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$364K |
| 2 |
Renaissance Technologies
New York
|
+$250K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$134K |
| 4 |
Goldman Sachs
New York
|
+$88K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$60.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$520K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$414K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$80K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$68.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.7K |
BLPH Hedge Fund Activity: Q1 2017 in Review
13 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q1 2017, worth a combined $22.2M — up 165% from $8.35M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BLPH and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $364K. The largest seller was Armistice Capital, exiting entirely with an estimated $520K sold.
- 13 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q1 2017, down from 15 in Q4 2016.
- Funds reported $22.2M of Bellerophon Therapeutics, Inc. stock for Q1 2017, up 165% quarter-over-quarter.
- 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q1 2017 and 5 closed out, a net change of -2 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q1 2017 was Vanguard Group, an estimated $364K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q1 2017 was Armistice Capital, an estimated $520K sold.
Based on aggregated 13F filings for Q1 2017.